Phase 4 N=30 Randomized Supportive Care

Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis

Muscle Cramp · Cirrhosis

Bottom Line

View on ClinicalTrials.gov: NCT03176966 ↗

Enrolled (actual)

Serious AEs

2.0%

Results posted

Oct 2022

Primary outcome: Primary: Frequency of Muscle Cramps as Assessed by Patient Survey — 1.14; 1.23 score on a scale

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Vitamin E (Drug); Ropinirole (Drug); Muscle cramp survey (Other)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Vanderbilt University Medical Center
Primary completion: Oct 2021

Outcome Measures

Outcome	Result	p-value
PRIMARY Frequency of Muscle Cramps as Assessed by Patient Survey	1.14; 1.23	—
SECONDARY Muscle Cramp Severity as Assessed by Patient Survey	6.57; 6.00	—

Summary

The investigator's aim is to compare the efficacy of Ropinirole (Requip) to vitamin E in the treatment of muscle cramps in cirrhotic patients.

Eligibility Criteria

Inclusion Criteria

Patients at least 18 years of age in the Vanderbilt Medical Center Hepatology Practice
diagnosis of cirrhosis
Self report regular muscle cramping

Exclusion Criteria

Patients without cirrhosis
Patients under the age of 18
Pregnant women

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03176966). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.